Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business.
$25.16+15.04%
报价 2026-11-06
市值
$987.3M
EV
$750.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -31.3%
$11.35$36.64
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ANROAlto Neuroscience, Inc. | $987.3M | +15.0% | – | 0% | – | – | – | |
| DRTSAlpha Tau Medical Ltd. | $1.27B | +3.2% | – | 0% | – | – | – | |
| SLNSilence Therapeutics plc | $931.9M | +0.1% | – | 51% | – | – | – | |
| CTNMContineum Therapeutics, Inc. Class A Common Stock | $336.6M | +8.1% | +15.0% | 0% | – | – | – | |
| DBVTDBV Technologies S.A. | $250M | +6.6% | – | -110.7% | – | – | – | |
| LRMRLarimar Therapeutics, Inc. | $248.3M | +3.0% | – | 0% | – | – | – | |
| AMRNAmarin Corporation plc | $240.1M | +0.3% | – | 65.7% | – | – | – | |
| ACIUAC Immune S.A. | $227M | +5.7% | – | 100% | – | – | – | |
| KRROKorro Bio, Inc. | $217.2M | +0.1% | -61.8% | 72.8% | – | – | – | |
| 同行中位数 | – | – | -23.4% | 25.5% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。